Search Result

Results for "

AMPA receptors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (2) Adenosine Receptor (1) Akt (7) AMPK (2) Antibiotic (1) Apoptosis (25) Autophagy (2) c-Met/HGFR (3) Calcium Channel (10) CaMK (2) Carbonic Anhydrase (7) Caspase (2) Cytochrome P450 (2) DNA/RNA Synthesis (1) Dopamine Receptor (1) Dopamine Transporter (1) Drug Derivative (2) Endogenous Metabolite (21) Environmental Pollutants (3) ERK (2) Ferroptosis (21) Fungal (1) GABA Receptor (9) Glutaminase (3) HIV Integrase (1) iGluR (183) Isotope-Labeled Compounds (13) Keap1-Nrf2 (2) Lipoxygenase (1) mGluR (1) MMP (5) MOFs (1) mTOR (2) NF-κB (5) Opioid Receptor (5) p38 MAPK (2) PARP (2) Phosphatase (2) Phosphodiesterase (PDE) (1) PI3K (7) PKC (3) Potassium Channel (7) Reactive Oxygen Species (ROS) (2) Reference Standards (25) Sodium Channel (9) Somatostatin Receptor (3) STING (2) TRP Channel (2) Tyrosinase (3) VEGFR (2)
By Research Areas:	Cancer (17) Cardiovascular Disease (6) Infection (2) Inflammation/Immunology (12) Metabolic Disease (9) Neurological Disease (189)

By Targets:

11β-HSD (2)

Adenosine Receptor (1)

Akt (7)

AMPK (2)

Antibiotic (1)

Apoptosis (25)

Autophagy (2)

c-Met/HGFR (3)

Calcium Channel (10)

CaMK (2)

Carbonic Anhydrase (7)

Caspase (2)

Cytochrome P450 (2)

DNA/RNA Synthesis (1)

Dopamine Receptor (1)

Dopamine Transporter (1)

Drug Derivative (2)

Endogenous Metabolite (21)

Environmental Pollutants (3)

ERK (2)

Ferroptosis (21)

Fungal (1)

GABA Receptor (9)

Glutaminase (3)

HIV Integrase (1)

iGluR (183)

Isotope-Labeled Compounds (13)

Keap1-Nrf2 (2)

Lipoxygenase (1)

mGluR (1)

MMP (5)

MOFs (1)

mTOR (2)

NF-κB (5)

Opioid Receptor (5)

p38 MAPK (2)

PARP (2)

Phosphatase (2)

Phosphodiesterase (PDE) (1)

PI3K (7)

PKC (3)

Potassium Channel (7)

Reactive Oxygen Species (ROS) (2)

Reference Standards (25)

Sodium Channel (9)

Somatostatin Receptor (3)

STING (2)

TRP Channel (2)

Tyrosinase (3)

VEGFR (2)

By Research Areas:

Cancer (17)

Cardiovascular Disease (6)

Infection (2)

Inflammation/Immunology (12)

Metabolic Disease (9)

Neurological Disease (189)

197

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-15068

NBQX Maximum Cited Publications 20 Publications Verification FG9202	iGluR	Neurological Disease
NBQX (FG9202) is a highly selective and competitive **AMPA receptor** antagonist. NBQX has neuroprotective and anticonvulsant activity .

HY-108599

DCP-LA 5+ Cited Publications FR236924	PKC CaMK Phosphatase Apoptosis	Neurological Disease
DCP-LA (FR236924), a linoleic acid derivative, selectively and directly activates PKCε. DCP-LA activates Ca( ²⁺)/calmodulin-dependent protein kinase II (CaMKII) and inhibits protein phosphatase-1 (PP-1) to stimulate AMPA receptor exocytosis. DCP-LA inhibits activation of caspase-3/-9 and protects neurons at least in part from oxidative stress-induced apoptosis .

HY-100815A

(S)-AMPA L-AMPA	iGluR	Neurological Disease
(S)-AMPA (L-AMPA), an active S-enantiomer of AMPA, is a potent and selective **AMPA receptor** agonist .

HY-15067

DNQX 10+ Cited Publications FG 9041	iGluR	Cancer
DNQX (FG 9041), a quinoxaline derivative, is a selective, potent competitive non-NMDA glutamate receptor antagonist (IC₅₀s = 0.5, 2 and 40 μM for AMPA, kainate and NMDA receptors, respectively) .

HY-115864

Osavampator TAK-653; NBI-1065845	iGluR Lipoxygenase	Neurological Disease
Osavampator (TAK-653) is a AMPA receptor positive allosteric modulator. Osavampator selectively binds to AMPA-R in a glutamate-dependent manner and induces Ca2+ influx in hGluA1i CHO cells (EC₅₀ = 3.3 μM). Osavampator improves learning and memory in many models. Osavampator is can be used for the research of depressive disorders .

HY-100815B

(RS)-AMPA (±)-AMPA	iGluR	Neurological Disease
(RS)-AMPA ((±)-AMPA) is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA does not interfere with binding sites for kainic acid or NMDA receptors .

HY-15068A

NBQX disodium Maximum Cited Publications 20 Publications Verification FG9202 disodium	iGluR	Neurological Disease
NBQX disodium (FG9202 disodium) is a highly selective and competitive **AMPA receptor** antagonist. NBQX disodium has neuroprotective and anticonvulsant activity .

HY-10933

CX516 2 Publications Verification BDP 12	iGluR	Neurological Disease
CX516 (BDP 12) is an ampakine and acts as an *AMPA* receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI) .

HY-101165

Cyclothiazide 2 Publications Verification	iGluR GABA Receptor	Neurological Disease
Cyclothiazide is a positive allosteric modulator of ionotropic *AMPA-type* glutamate receptors. Cyclothiazide inhibits GABA_A receptors. Cyclothiazide is frequently used to produce a fast inhibition of AMPA receptor desensitization and a much slower potentiation of the AMPA current. Cyclothiazide can potentiate responses to kainate in hippocampal neurons. Cyclothiazide has effects on glutamatergic neurotransmission. Cyclothiazide also induces epileptiform EEG activity accompanying behavioral seizures .

HY-118424

JNJ-55511118	iGluR	Neurological Disease Metabolic Disease
JNJ-55511118 is a selective TARP γ-8 binding *AMPA* receptor modulator with oral bioavailability and blood-brain barrier permeability, with a K_i of 26 nM. JNJ-55511118 reduces voluntary intake of sweetened alcohol in male mice. In rodent models, JNJ-55511118 inhibits hippocampal neurotransmission, reduces specific electroencephalogram frequency bands, induces transient hyperlocomotion, impairs learning and memory abilities, and exerts anticonvulsant effects. JNJ-55511118 is applicable to research related to alcohol use disorder and seizures .

HY-101528

IDRA 21	iGluR	Neurological Disease
IDRA 21 is a positive and orally active modulator of the *AMPA* receptor. IDRA 21 facilitates excitatory neurotransmission via GluR1/2 receptors. IDRA 21 has the potential for the research of cognitive/memory disorders, including those associated with aging .

HY-12509

PEPA	iGluR	Neurological Disease
PEPA is an **AMPA receptor** allosteric potentiator. PEPA shows preferential action of PEPA on the flop form of AMPA receptors. PEPA is a more potent suppressor of desensitization of receptors containing GluR3 and GluR4 as opposed to those containing GluR1. PEPA has antianxiety effects .

HY-175443

AMPA-IN-3	iGluR	Neurological Disease
AMPA-IN-3 is an *AMPA* receptor inhibitor. AMPA-IN-3 inhibits TARP J2-dependent AMPA receptor activity with a pIC₅₀ value of 10.7. A AMPA-IN-3 can be used for the research of neurological disease .

HY-12506A

Naspm trihydrochloride 5+ Cited Publications 1-Naphthylacetyl spermine trihydrochloride	iGluR	Neurological Disease
Naspm trihydrochloride (1-Naphthylacetyl spermine trihydrochloride), a synthetic analogue of Joro spider toxin, is a calcium permeable AMPA (CP-AMPA) receptors antagonist.

HY-12506

Naspm 5+ Cited Publications 1-Naphthylacetyl spermine	iGluR	Neurological Disease
Naspm (1-Naphthyl acetyl spermine), a synthetic analogue of Joro spider toxin, is a calcium permeable AMPA (CP-AMPA) receptors antagonist.

HY-10934

Mibampator LY451395	iGluR	Neurological Disease
Mibampator (LY451395) is a potent and highly selective potentiator of the AMPA receptors.

HY-171844

CX1739	iGluR	Neurological Disease Inflammation/Immunology
CX1739 is an orally active, blood-brain barrier permeable, low-efficacy AMPA-glutamate receptor (AMPAR) potentiator. CX1739 enhances excitatory neurotransmission by potentiating glutamate-induced excitatory currents and promoting in vivo long-term potentiation. CX1739 eliminates amphetamine-induced locomotor activity, reverses opioid-, pentobarbital- and ethanol-induced respiratory depression, and exerts pro-cognitive effects in animals. CX1739 impairs motor function recovery and increases the risk of post-injury complications. CX1739 can be used in research related to attention-deficit/hyperactivity disorder, dementia, respiratory depression and spinal cord injury .

HY-139897

CX 717	iGluR	Neurological Disease
CX 717 is a positive allosteric modulator of **AMPA receptor**. Antidepressant-like effect. CX 717 can be used for the research of adult attention deficit hyperactivity disorder (ADHD) .

HY-125931

Unifiram DM232	iGluR	Neurological Disease Inflammation/Immunology
Unifiram (DM232) is a *AMPA* receptor activator and cognitive enhancer. Unifiram activates the *AMPA*-mediated neurotransmission system. Unifiram reverses NBQX-induced amnesia in the passive avoidance test in mice. Unifiram reverses the antagonistic effect of kynurenic acid on NMDA-mediated [ ³H]NA release in rat hippocampal slices. Unifiram enhances excitatory synaptic transmission in the rat hippocampus in vitro. Unifiram can be used in studies related to amnesia and cognitive dysfunction, including age-related memory decline, neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease, multiple sclerosis, schizophrenia, and attention deficit hyperactivity disorder .

HY-100785

gamma-DGG γDGG; γ-D-Glutamylglycine	iGluR	Neurological Disease
gamma-DGG is a competitive **AMPA receptor** blocker.

HY-P2259

TAT-GluA2 3Y 2 Publications Verification	iGluR HIV Integrase Adenosine Receptor	Cardiovascular Disease Neurological Disease
TAT-GluA2 3Y is a blood-brain barrier-permeable *AMPA* receptor inhibitory peptide that crosses cell membranes via the HIV-1 TAT protein domain. TAT-GluA2 3Y blocks the endocytosis of *AMPA* receptors, including the internalization of GluA1/GluA2 subunits, by disrupting interactions with the AP2, Brag2 and Syt3-GluA2 complexes, while also inhibiting long-term depression. TAT-GluA2 3Y blocks hypoxia-mediated AMPAR internalization, alleviates A1R-induced persistent synaptic inhibition, and reduces cerebral ischemic volume, neurological deficits and spatial memory deficits. TAT-GluA2 3Y blocks the effect of NLRP3 deficiency on fear generalization, inhibits amphetamine-induced behavioral/neurochemical sensitization, weakens the unconditioned stimulus-conditioned stimulus association of morphine, and promotes the extinction of morphine CPP. TAT-GluA2 3Y can be used in studies related to fear generalization, ischemic stroke, hypoxia, drug addiction and opioid addiction .

HY-107520

MNI-caged-L-glutamate	Drug Derivative	Neurological Disease
MNI-caged-L-glutamate is an inert photolabile glutamate precursor. MNI-caged-L-glutamate does not modulate NMDA and *AMPA* receptor function in cultured neurones. MNI-caged-L-glutamate can be used for research on neurotransmitters .

HY-177873

AMPA receptor modulator-10	iGluR	Neurological Disease
AMPA receptor modulator-10 (Compound 9a) is an orally active **AMPA receptor (AMPAR*) positive allosteric modulator. AMPA* receptor modulator-10 exhibits potent activity (pEC₅₀ = 5.0) on the GluA2 subtype of AMPAR, significantly enhancing glutamate-induced calcium influx and current responses. AMPA receptor modulator-10 can reverse the memory impairment induced by Scopolamine (HY-N0296) and enhance cognitive function. AMPA receptor modulator-10 can be used for the research of neurological disease, such as schizophrenia .

HY-112781

Pesampator PF-04958242	iGluR	Neurological Disease
Pesampator (PF-04958242) is a potent and highly selective positive allosteric modulator of **AMPA receptor** (an AMPA potentiator) with an EC₅₀ of 310 nM and a K_i of 170 nM .

HY-122742

HBT1	iGluR	Neurological Disease
HBT1 is an effective AMPA receptor *AMPA-R* potentiator. HBT1 specifically binds to the ligand-binding domain (LBD) of AMPAR and enhances receptor activity only when AMPA is present., HBT1 has almost no agonistic effect (i.e., reaching the optimal concentration, and then the efficacy decreases as the concentration continues to increase) compared with traditional AMPA-R potentiator, avoiding the bell-shaped reaction of brain-derived neurotrophic factor (BDNF) production in primary neurons. HBT1 can be applicable to a wider range of neurological and psychiatric diseases (such as depression, Alzheimer's disease, etc.) .

HY-18663

CP-465022 1 Publications Verification	iGluR	Neurological Disease
CP-465022 is a potent, and selective noncompetitive **AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC₅₀** of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .

HY-108707

LY3130481 1 Publications Verification	iGluR	Neurological Disease
LY3130481 is an orally available *AMPA* receptor antagonist, selectively inhibiting the IC₅₀ value of AMPA/TARP γ-8 at 65 nM. LY3130481 has anticonvulsant, antiepileptic, and pain-relieving effects .

HY-103230

IEM-1460	iGluR	Neurological Disease
IEM-1460 blocks both *AMPA* and NMDA glutamate receptor with anticonvulsant effect in vivo .

HY-10937

Farampator CX-691; Org24448	iGluR	Neurological Disease
Farampator (CX-691;Org24448) is an *AMPA* receptor positive modulator.

HY-10935

LY450108 1 Publications Verification	iGluR	Neurological Disease
LY450108 is a potent *AMPA* receptor potentiator. LY450108 has the potential for depression and Parkinson's disease research .

HY-15072

Zonampanel YM 872	iGluR	Metabolic Disease
Zonampanel (YM 872) is a selective antagonist of the glutamate receptor subtype, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor.

HY-103233

DNQX disodium salt 10+ Cited Publications FG 9041 disodium salt	iGluR	Cancer
DNQX (FG 9041) disodium salt, a quinoxaline derivative, is a selective, potent competitive non-NMDA glutamate receptor antagonist (IC₅₀s = 0.5, 2 and 40 μM for AMPA, kainate and NMDA receptors, respectively) .

HY-16713A

(S)-(-)-5-Fluorowillardiine (hydrochloride) (5S)-Fluorowillardiine hydrochloride; (S)-5-Fluorowillardiine hydrochloride	iGluR	Neurological Disease
(S)-(-)-5-Fluorowillardiine ((5S)-Fluorowillardiine; (S)-5-Fluorowillardiine) hydrochloride is a potent, highly selective non-NMDA ionotropic glutamate receptor (iGluR, AMPA/Kainate receptor) agonist . (S)-(-)-5-Fluorowillardiine hydrochloride activates high-affinity AMPA-preferring receptors (EC₅₀ = 0.70 μM) and low-affinity kainate-preferring receptors (EC₅₀ = 170 μM), thereby inducing biphasic dose-dependent neurotoxicity/excitotoxicity. (S)-(-)-5-Fluorowillardiine hydrochloride is applicable to research related to schizophrenia, temporal lobe epilepsy, and bipolar disorder .

HY-15071

YM90K	iGluR	Neurological Disease
YM90K is a potent and selective **AMPA receptor antagonist with a K_i** of 84 nM. YM90K is less potent in inhibiting kainate (K_i of 2.2 μM) and NMDA (K_i of 37 μM) receptors. YM90K has neuroprotective actions .

HY-12508

CMPDA	iGluR	Neurological Disease
CMPDA is a positive allosteric modulator of AMPA receptors with EC50s of 45.4 ± 4.2 nM/63.4 ± 5.6 nM for GluA2i/GluA2o receptor.

HY-18689

SYM2206	iGluR	Neurological Disease
SYM2206 is a potent and non-competitive **AMPA receptor antagonist, with an IC₅₀** of 1.6 μM. SYM2206 blocks Na_v1.6-mediated persistent currents .

HY-107606A

UBP301 hydrochloride	iGluR	Neurological Disease
UBP301 hydrochloride is a potent and selective antagonist of kainate receptor with IC₅₀ and K_D of 164 μM and 5.94 μM, respectively. UBP301 hydrochloride has ～30-fold selectivity of kainate receptor over AMPA receptor. UBP301 hydrochloride is the derivative of willardiine .

HY-136275

AMPA receptor modulator-2	iGluR	Others
AMPA receptor modulator-2 (Example 134) is a **AMPA receptor modulator, with a pIC₅₀** of 10.1 for TARPγ8 dependent AMPA receptor . pIC₅₀ = -lgIC₅₀.

HY-101216

Org-26576	iGluR	Neurological Disease
Org-26576 is a *AMPA* receptor positive allosteric modulator.

HY-19433A

(S)-ATPO	iGluR	Neurological Disease
(S)-ATPO is the (S)-enantiomer of ATPO, which is a competitive antagonist at GluR1-4 (AMPA-preferring) receptors .

HY-103232

IEM-1925 bromide	mGluR	Neurological Disease
IEM-1925 bromide is an orally active glutamate receptor antagonist, increases the latent period and decreases the duration of status epilepticus in rats in a lithium-pilocarpine model of epilepsy .

HY-101363

1-BCP Piperonylic acid piperidide	iGluR	Neurological Disease
1-BCP (Piperonylic acid piperidide) is a centrally active agent that modulates **AMPA receptor** gated currents. 1-BCP is a memory-enhancing agent .

HY-105860

Selurampanel BGG 492	iGluR	Neurological Disease
Selurampanel (BGG 492) is an orally active and competitive **AMPA receptor antagonist with an IC₅₀** of 190 nM. Selurampanel has reasonable blood-brain barrier penetration. Selurampanel can be used for epilepsy research .

HY-103235

NPEC-caged-(S)-AMPA	iGluR	Neurological Disease
NPEC- caged-(S)-AMPA, a caged neurotransmitter analog, is a NPEC photoprotecting group caged the (S)-AMPA (HY-100815A) to make caged ligands specific for glutamate receptor sub-types. NPEC- caged-(S)-AMPA selectively activates **AMPA receptor** .

HY-145761

AMPA-IN-1	iGluR	Neurological Disease
AMPA-IN-1 is a potent inhibitor of *AMPA* receptor. AMPA receptors are receptors that are widely expressed in the brain, and play a central role in the regulation of fast excitatory synaptic transmission and synaptic plasticity. AMPA-IN-1 has the potential for the research of various central diseases including epilepsy (extracted from patent WO2017082288A1, compound 14) .

HY-155628

AMPA receptor modulator-6	iGluR	Others
AMPA receptor modulator-6 is an *AMPA* receptor positive allosteric modulator (PAM). AMPA receptor modulator-6 can be used in the study of neurological diseases .

HY-100815C

(RS)-AMPA hydrobromide (±)-AMPA hydrobromide	iGluR	Neurological Disease
(RS)-AMPA hydrobromide ((±)-AMPA hydrobromide) is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA hydrobromide does not interfere with binding sites for kainic acid or NMDA receptors .

HY-14451

PF-4778574	iGluR	Neurological Disease
PF-4778574 is a positive allosteric modulation of *AMPA* receptor with EC₅₀ of 45 to 919 nM in differenct cells.

HY-114975

EGIS-8332	iGluR	Neurological Disease
EGIS-8332 is a non-competitive *AMPA* receptor antagonist. EGIS-8332 inhibits AMPA currents in rat cerebellar Purkinje cells and inhibited the AMPA- and Quisqualate-induced excitotoxicity in primary cultures of telencephalon neurons (IC₅₀ = 5.1-9.0 μM). EGIS-8332 exhibits anticonvulsant and neuroprotective effects. EGIS-8332 can be used for the research of neurological disease .

HY-114576

Nooglutil Nooglutyl; ONK-10	iGluR Dopamine Receptor	Neurological Disease
Nooglutil (Nooglutyl; ONK-10) is a positive modulator of AMPA-type glutamate receptors (AMPARs). Nooglutil also regulates dopamine D2 receptor function to exert anxiolytic effects. Nooglutil is promising for research of neurodegenerative disorders (e.g., Alzheimer’s disease) .

Cat. No.	Nombre del producto	Target	Research Area

HY-P2259

TAT-GluA2 3Y 2 Publications Verification	iGluR HIV Integrase Adenosine Receptor	Cardiovascular Disease Neurological Disease
TAT-GluA2 3Y is a blood-brain barrier-permeable *AMPA* receptor inhibitory peptide that crosses cell membranes via the HIV-1 TAT protein domain. TAT-GluA2 3Y blocks the endocytosis of *AMPA* receptors, including the internalization of GluA1/GluA2 subunits, by disrupting interactions with the AP2, Brag2 and Syt3-GluA2 complexes, while also inhibiting long-term depression. TAT-GluA2 3Y blocks hypoxia-mediated AMPAR internalization, alleviates A1R-induced persistent synaptic inhibition, and reduces cerebral ischemic volume, neurological deficits and spatial memory deficits. TAT-GluA2 3Y blocks the effect of NLRP3 deficiency on fear generalization, inhibits amphetamine-induced behavioral/neurochemical sensitization, weakens the unconditioned stimulus-conditioned stimulus association of morphine, and promotes the extinction of morphine CPP. TAT-GluA2 3Y can be used in studies related to fear generalization, ischemic stroke, hypoxia, drug addiction and opioid addiction .

HY-P1057

Pep4c	iGluR	Neurological Disease
Pep4c is an inactive control peptide for Pep2m (HY-P1058). Pep4c lacks functional activity to disrupt Protein Interacting with C Kinase 1 (PICK1)-AMPA receptor (GluA2) or N-ethylmaleimide-sensitive factor (NSF)-GluA2 interactions. Pep4c is used as a negative control in experiments to validate the specificity of Pep2m's effects on *AMPA* receptor trafficking and synaptic plasticity ^{[1] [2] [3] [4] [5] [6]}.

HY-P1367

Pep1-TGL	Peptides	Neurological Disease
Pep1-TGL is a synthetic peptide containing the TGL motif from the C-terminus of the AMPA receptor GluA1 subunit .

HY-P1055

Pep2-SVKE	iGluR	Neurological Disease
Pep2-SVKE is an inactive control peptide for pep2-SVKI (HY-P1056). Pep2-SVKE is an inhibitory peptide corresponding to the last 10 amino acids of the C-terminus of the GluR2 *AMPA* receptor subunit. Pep2-SVKE does not block *AMPA*-mediated [ ³H]DA exocytosis. Pep2-SVKE does not bind to GRIP or PICK43 and does not block retention of PICK1 by GST-GluR2 and LTD ^{[1] [2] [3] [4] [5]}.

HY-P3340

Leptin (116-130)	iGluR	Neurological Disease
Leptin (116-130) is a bioactive leptin fragment. Leptin (116-130) promotes AMPA receptor trafficking to synapses and facilitate activity-dependent hippocampal synaptic plasticity. Leptin (116-130) prevents hippocampal synaptic disruption and neuronal cell death in models of amyloid toxicity. Leptin (116-130) has the potential for the research of Alzheimer's disease (AD) .

HY-P3355

p-fin4	iGluR	Neurological Disease
p-fin4 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 0.4 μM. p-fin4 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p-fin4 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .

HY-P5487

GluR23Y	iGluR	Others
GluR23Y is a biological active peptide. (This GluR23Y peptide was used in ELISA cell-surface assay for the insulin-stimulated endocytosis of native AMPA receptors in cultured hippocampal neurons. GluR23Y prevented any insulin-induced reduction. The blockade of insulin action was observed when the GluR23Y peptide was delivered into neurons by fusing it to the membrane transduction domain of HIV-1.)

HY-P3354

p3Ysh-3	iGluR	Neurological Disease
p3Ysh-3 is a peptide inhibitor of STEP Phosphatase-GluA2 AMPA receptor interaction with a Ki of 1.09 μM. p3Ysh-3 restores the memory deficits and displays anxiolytic and antidepressant effects in a scopolamine-treated rat model. p3Ysh-3 is a promising lead compound for novel cognitive enhancers and/or behavioral modulators .

HY-P1058

Pep2m	iGluR	Neurological Disease
Pep2m is a peptide receptor inhibitor. Pep2m inhibits the interaction between the C-terminus of the AMPA-type glutamate receptor (GluA2) subunit and N-ethylmaleimide-sensitive fusion protein (NSF). Pep2m prevents synaptic long-term depression (LTD). Pep2m can reduce postsynaptic currents in neurons, AMPA-mediated currents in cultured hippocampal neurons, and AMPA receptor surface expression ^{[1] [2] [3] [4] [5]}.

HY-P1056

pep2-SVKI	iGluR	Neurological Disease
pep2-SVKI is a selective peptide inhibitor. pep2-SVKI inhibits the binding of AMPA-type glutamate receptor (GluA2) (C-terminal PDZ site) to glutamate receptor interacting protein (GRIP), AMPA receptor binding protein (ABP), and C-kinase interacting protein (PICK1). pep2-SVKI increases the amplitude of AMPA receptor-mediated currents and blocks long-term depression (LTD). pep2-SVKI can be used to study neurological diseases .

HY-P1059

Pep2-AVKI	iGluR	Neurological Disease
Pep2-AVKI is a selective peptide inhibitor of the binding of the AMPA receptor subunit (GluR2) at the C-terminal PDZ site to C-kinase (PICK1). Pep2-AVKI does not affect the binding of (AMPA-type glutamate receptor) GluA2 to GRIP or ABP. Pep2-AVKI does not increase the amplitude of AMPA currents. pep2-AVKI can be used to study neurological diseases .

HY-P11848

P3LC7LC-P	iGluR Apoptosis Reactive Oxygen Species (ROS)	Cardiovascular Disease Neurological Disease
P3LC7LC-P is a blood-brain barrier-permeable BRAG2 ligand with a K_D of 6.14 μM. P3LC7LC-P binds to BRAG2, thereby disrupting its interaction with the GluA2 subunit of the **AMPA receptor and inhibiting glutamate-induced GluA2 endocytosis. P3LC7LC-P exerts neuroprotective effects in oxygen-glucose deprivation-induced and glutamate-induced neurotoxicity models, reduces ROS accumulation and inhibits apoptosis**, and reduces cerebral infarct size in a rat model of transient middle cerebral artery occlusion. P3LC7LC-P can be used for the research of ischemic stroke .

Cat. No.	Nombre del producto	Category	Target	Chemical Structure

HY-14608

L-Glutamic acid Maximum Cited Publications 15 Publications Verification	Structural Classification Microorganisms Disease markers Endocrine diseases Amino acids Nervous System Disorder Endogenous metabolite Cardiovascular System Disorder Cancer Source Classification	Environmental Pollutants Endogenous Metabolite iGluR Ferroptosis Apoptosis
L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases. L-Glutamic acid acts at ionotropic and metabotropic glutamate receptors .

HY-14608A

L-Glutamic acid monosodium salt 10+ Cited Publications	Structural Classification Microorganisms other families Animals Amino acids Plants Source Classification	Environmental Pollutants iGluR Apoptosis Ferroptosis Endogenous Metabolite
L-Glutamic acid monosodium salt is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium salt has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium salt can be used in the study of neurological diseases. L-Glutamic acid monosodium salt acts at ionotropic and metabotropic glutamate receptors .

HY-W015309

Decanoic acid 4 Publications Verification	Structural Classification Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Biological Pesticide Research Source Classification Agricultural Research	Environmental Pollutants Endogenous Metabolite iGluR Glutaminase c-Met/HGFR Tyrosinase
Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of *AMPA* receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .

HY-116330A

Hyperforin dicyclohexylammonium salt 3 Publications Verification Hyperforin DCHA	Productos naturales Guttiferae Hyperlcurn perforatum L. Plants Source Classification	TRP Channel Calcium Channel
Hyperforin dicyclohexylammonium salt (Hyperforin DCHA) is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin dicyclohexylammonium salt modulates Ca ²⁺ levels by activating Ca ²⁺-conducting non-selective canonical TRPC6 channels. Hyperforin dicyclohexylammonium salt also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin dicyclohexylammonium salt modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model .

HY-14608R

L-Glutamic acid (Standard)	Structural Classification Microorganisms Disease markers Endocrine diseases Amino acids Nervous System Disorder Endogenous metabolite Cardiovascular System Disorder Cancer Source Classification	Reference Standards Endogenous Metabolite iGluR Ferroptosis Apoptosis
L-Glutamic acid (Standard) is the analytical standard of L-Glutamic acid. This product is intended for research and analytical applications. L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases . IC₅₀ & Target:DA . In Vitro: L-Glutamic acid (120, 500, 750, 1000 mg/dL) can reduce the harmful effect of lithium on the embryonic development of Xenopus Xenopus . L-Glutamic acid (2, 5, 10, 20 mM, 24-48 h) can induce neuroexcitotoxicity in neuroblastoma . In Vivo: L-Glutamic acid (3 g/kg, subcutaneous injection) can promote excitotoxic degeneration of retinal ganglion cells in mice . L-Glutamic acid (750 mg/kg, intraperitoneal injection) can reduce and inhibit oxidative stress induced by chlorpyrifos (CPF) in rats .

HY-N0660

Jujuboside B	Cardiovascular Disease Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Plants Disease Research Fields Source Classification	Apoptosis PARP Caspase AMPK Autophagy VEGFR Keap1-Nrf2 STING 11β-HSD Ferroptosis PI3K Akt p38 MAPK ERK
Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of *AMPA* receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM_2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes .

HY-14608AR

L-Glutamic acid monosodium salt (Standard)	Structural Classification Microorganisms other families Animals Amino acids Plants Source Classification	Reference Standards iGluR Apoptosis Ferroptosis Endogenous Metabolite
L-Glutamic acid (monosodium salt) (Standard) is the analytical standard of L-Glutamic acid (monosodium salt). This product is intended for research and analytical applications. L-Glutamic acid monosodium salt is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium salt has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium salt can be used in the study of neurological diseases .

HY-116330AR

Hyperforin dicyclohexylammonium salt (Standard) Hyperforin DCHA (Standard)	Structural Classification Productos naturales Guttiferae Hyperlcurn perforatum L. Plants Source Classification	Reference Standards TRP Channel Calcium Channel
Hyperforin dicyclohexylammonium salt (Standard) is the analytical standard of Hyperforin dicyclohexylammonium salt. This product is intended for research and analytical applications. Hyperforin dicyclohexylammonium salt (Hyperforin DCHA) is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin dicyclohexylammonium salt modulates Ca ²⁺ levels by activating Ca ²⁺-conducting non-selective canonical TRPC6 channels. Hyperforin dicyclohexylammonium salt also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin dicyclohexylammonium salt modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model .

HY-W015309R

Decanoic acid (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards iGluR Tyrosinase c-Met/HGFR Glutaminase
Decanoic acid (Standard) is the analytical standard of Decanoic acid. This product is intended for research and analytical applications. Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .

HY-N0660R

Jujuboside B (Standard)	Triterpenes Structural Classification other families Terpenoids Plants Source Classification	Reference Standards ERK p38 MAPK Akt PI3K 11β-HSD STING VEGFR Ferroptosis Autophagy Apoptosis Keap1-Nrf2 Caspase PARP AMPK
Jujuboside B (Standard) is the analytical standard of Jujuboside B. This product is intended for research and analytical applications. Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of *AMPA* receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM_2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes.

Cat. No.	Nombre del producto	Chemical Structure

HY-14608S5

L-Glutamic acid-13C5 1 Publications Verification
L-Glutamic acid- ¹³C₅ is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S7

L-Glutamic acid-d5
L-Glutamic acid-d₅ is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S8

L-Glutamic acid-d3
L-Glutamic acid-d₃ is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S3

L-Glutamic acid-13C5,15N
L-Glutamic acid- ¹³C₅, ¹⁵N is the ¹³C- and ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-W015309S1

Decanoic acid-d19
Decanoic acid-d₁₉9 is the deuterium labeled Decanoic acid. Decanoic acid, a component of medium chain triclycerides, is a brain-penetrant and non-competitive inhibitor of AMPA receptor. Decanoic acid has antiseizure effects .

HY-14608S

L-Glutamic acid-13C
L-Glutamic acid- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S2

L-Glutamic acid-15N
L-Glutamic acid- ¹⁵N is the ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals .

HY-14608S1

L-Glutamic acid-1-13C
L-Glutamic acid-1- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S6

L-Glutamic acid-5-13C
L-Glutamic acid-5- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-W266188

Decanoic acid-13C

Decanoic acid- ¹³C is the ¹³C-labeled Decanoic acid (HY-W015309). Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy .

HY-W015309S3

Decanoic acid-d5
Decanoic acid-d₅ is the deuterium labeled Decanoic acid. Decanoic acid, a component of medium chain triclycerides, is a brain-penetrant and non-competitive inhibitor of AMPA receptor. Decanoic acid has antiseizure effects .

HY-14608S4

L-Glutamic acid-13C5,15N,d5
L-Glutamic acid- ¹³C₅, ¹⁵N,d₅ is the deuterium, ¹³C-, and 15-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-W015309S

Decanoic acid-d3
Decanoic acid-d₃ is the deuterium labeled Decanoic acid. Decanoic acid, a component of medium chain triclycerides, is a brain-penetrant and non-competitive inhibitor of AMPA receptor. Decanoic acid has antiseizure effects .

HY-14608S10

L-Glutamic acid-13C2
L-Glutamic acid- ¹³C₂ is the ¹³C labeled L-Glutamic acid . L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals .

HY-B0122S

Topiramate-13C6

Topiramate-13C6 (McN 4853-13C6) is the ¹³C labeled isotope of Topiramate (HY-B0122). Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

HY-90003S

Tianeptine-d12

Tianeptine-d₁₂ is a deuterated analog of Tianeptine (HY-90003).Tianeptine is an atypical antidepressant. Tianeptine is a moderate-intensity agonist of the μ-opioid receptor (MOR), and to a lesser extent, is an agonist of the δ-opioid receptor (DOR). Tianeptine is a glutamate modulator that can enhance AMPA receptor and antagonize NMDA receptor. Tianeptine increases sensitivity of the α1 adrenergic receptor, which only manifests in chronic treatment. Tianeptine exerts neuroprotective effects under stress/inflammation-induced conditions, exhibiting anti-inflammatory and antioxidant properties. Tianeptine inhibits MMP-9 by suppressing the PI3K/Akt-mediated NF-κB pathway. Tianeptine can be used to alleviate symptoms of depression and anxiety, but does not cause sedative effects.

HY-W015309S2

Decanoic acid-d2
Decanoic acid-d₂ is the deuterium labeled Decanoic acid. Decanoic acid, a component of medium chain triclycerides, is a brain-penetrant and non-competitive inhibitor of AMPA receptor. Decanoic acid has antiseizure effects .

HY-10933S

CX516-d10
CX516-d₁₀ is the deuterium labeled CX516. CX516 (BDP 12) is an ampakine and acts as an AMPA receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI) .

HY-B0122S1

Topiramate-13C

Topiramate- ¹³C (McN 4853- ¹³C) is ¹³C labeled Topiramate. Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .

HY-14608S9

L-Glutamic acid-15N,d5
L-Glutamic acid- ¹⁵N,d₅ is the deuterium and ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-W016145S

L-Glutamic acid-13C5 hydrate salt

L-Glutamic acid- ¹³C₅ hydrate salt is the ¹³C labeled L-Glutamic acid hydrate salt. L-Glutamic acid monosodium hydrate is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium hydrate has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium hydrate can be used in the study of neurological diseases. L-Glutamic acid monosodium hydrate acts at ionotropic and?metabotropic glutamate receptors.

HY-144224S

Tianeptine-d6 hydrochloride

Tianeptine-d₆ hydrochloride is the deuterium labeled Tianeptine hydrochloride. Tianeptine hydrochloride is an atypical antidepressant. Tianeptine hydrochloride is a moderate-intensity agonist of the μ-opioid receptor (MOR), and to a lesser extent, is an agonist of the δ-opioid receptor (DOR). Tianeptine hydrochloride is a glutamate modulator that can enhance AMPA receptor and antagonize NMDA receptor. Tianeptine hydrochloride increases sensitivity of the α1 adrenergic receptor, which only manifests in chronic treatment. Tianeptine hydrochloride exerts neuroprotective effects under stress/inflammation-induced conditions, exhibiting anti-inflammatory and antioxidant properties. Tianeptine hydrochloride inhibits MMP-9 by suppressing the PI3K/Akt-mediated NF-κB pathway. Tianeptine hydrochloride can be used to alleviate symptoms of depression and anxiety, but does not cause sedative effects.

Consulta en línea

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones